Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
TRANSFORM-1
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
- NCT04472598 ↗
- Completed
- AbbVie
- Deep
We haven't built an HCP commentary report on TRANSFORM-1 (ruxolitinib and navitoclax in Myelofibrosis (MF)) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TRANSFORM-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 32 | |
| Podcasts | 21 | |
| X threads | 20 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Myelofibrosis (MF)
- Interventions
- Placebo for Navitoclax; Ruxolitinib; Navitoclax
- Arms
- Placebo for Navitoclax + Ruxolitinib · Active comparator
- Navitoclax + Ruxolitinib · Experimental
- Enrollment
- 252
- Primary outcomes
- Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24 (SVR35W24)
- Sponsor
- AbbVie
- Start
- Sep 29, 2020
- Primary completion
- Apr 13, 2023
- Results posted
- Yes
- Registry record
- NCT04472598 · updated Mar 23, 2026
Publications
linked from the registry- Pemmaraju N, Mead AJ, Somervaille TCP, Palandri F, Koschmieder S, Delage R, Kiladjian JJ, Benton C, Tantravahi SK, Lavi N, Yeh SP, Gomez Casares MT, Ammatuna E, McDonald A, Yoon SS, Kirito K, Devos T, Perkins A, Radinoff A, Sevindik OG, Bogdanovic A, Moskal R, Harb JG, Murray B, Jiang Q, Chopra AS, Papadopoulos EJ, Potluri J, Passamonti F. TRANSFORM-1 phase 3 study: efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis. Blood. 2026 Oct 15;148(16):2029-2042. doi: 10.1182/blood.2025032360. PubMed 42378247